Bristol-Myers Squibb inked a deal with Isis Pharmaceuticals to collaborate on the discovery, development and commercialization of antisense drugs targeting the gene PCSK9 for cardiovascular disease. PCSK9 helps regulate the amount of cholesterol in the bloodstream. Bristol-Myers Squibb will pay Isis a $15 million upfront and provide $9 million in research funding for three years. Isis will also receive up to $168 million for the achievement of pre-specified development and regulatory milestones for the first drug in the collaboration.
- see the release for more
Isis touts positive cholesterol data in LDL study. Report
Exelixis, BMS partner on cholesterol-lowering drugs. Report
Better times ahead for BMS? Report